Clinical trials have demonstrated that treatment with tyrosine kinase inhibitors (TKIs) improved progression-free survival in NSCLC patients who harbor epidermal growth factor receptor (EGFR) mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.